Chemotherapy drug liposome and preparation method thereof

The liposomes prepared by the magnesium ion weak acid salt gradient method use magnesium ions to form complexes with anthraquinone drugs, solving the problem of slow release of drugs in the acidic microenvironment of tumors, improving the efficacy of tumor chemotherapy and enhancing the The stability of the drug.

CN118903012APending Publication Date: 2024-11-08THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410951892.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to effectively carry weakly basic anthraquinone drugs and achieve slow release of drugs in the acidic microenvironment of tumors, and the stability of transition metal ion gradient liposomes is poor and hydrolyzed precipitation reactions are prone to occur during the preparation process.

Method used

The magnesium ion weak acid salt gradient method is used to prepare liposomes. By adding magnesium ions to the internal aqueous phase and forming a complex with anthraquinone drugs, the pH gradient is used to achieve stable loading and slow release of drugs, and improve the intracellular drugs in tumor cells. degree of intake.

Benefits of technology

It realizes stable loading of drugs under physiologically weak alkaline conditions and is slowly released in the acidic microenvironment of tumors, improves the efficacy of tumor chemotherapy, meets the drug delivery and release needs in tumor treatment, and avoids drugs in organisms. Risk of instability and allergic reactions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004947460940000011
    Figure HDA0004947460940000011
  • Figure HDA0004947460940000012
    Figure HDA0004947460940000012
  • Figure HDA0004947460940000013
    Figure HDA0004947460940000013
Patent Text Reader

Abstract

The invention belongs to the technical field of drugs, and particularly relates to a chemotherapeutic drug liposome and a preparation method thereof. Compared with the prior art, the preparation method has the advantages that remote loading of weak-base anthraquinone drug molecules by the liposome can be effectively realized by utilizing the liposome with the inner water phase containing the magnesium ion weak acid salt through a magnesium ion weak acid salt gradient method, so that the obtained chemotherapy drug liposome not only can effectively entrap anthraquinone drugs, but also can effectively entrap the anthraquinone drugs; the chemotherapy drug liposome entrapped with the magnesium ion anthraquinone drug is stable under a physiologically weak alkaline condition, can slowly release the drug in a tumor acidic microenvironment, has a tumor acidic microenvironment response release function, can improve the uptake degree of drug molecules in tumor cells, improves the tumor chemotherapy efficacy, and has a wide application prospect. And the requirements of delivery and release of chemotherapeutic drugs in tumors in tumor treatment are met.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceutical technology, and in particular relates to a chemotherapeutic drug liposome and a preparation method thereof. Background Art

[0002] Cancer seriously endangers people's life and health. Chemotherapy is one of the main treatments for tumors. Various anthracyclines, such as doxorubicin, epirubicin, daunorubicin, etc., have a broad-spectrum tumor cell killing effect and are widely used in the treatment of tumors in clinical practice. However, ordinary injections of these drugs still have many toxic and side effects in clinical practice. Drug carriers are currently commonly used technical means to reduce the toxic and side effects of chemotherapy drugs. Among them, liposomes are drug carriers with good drugability and are widely used in the pharmaceutical industry.

[0003] The pH gradient method or the ammonium sulfate gradient method can effectively load the amphiphilic weakly basic molecules remotely in the liposomes (US Pat. No. 5,192,549). The weakly basic anthracycline molecules enter the aqueous phase in the liposomes under the drive of the pH or ammonium sulfate gradient, and become cationic after combining with protons, making it difficult to pass through the lipid bilayer, and can combine with the anions present in the inner aqueous phase to form a precipitate, thereby being stably retained in the liposomes. Compared with ordinary injection formulations, the anthracycline liposomes prepared by this method can significantly improve the efficacy of tumor treatment and reduce toxic side effects. Among them, doxorubicin liposomes are already on the market and can significantly reduce the cardiac toxicity of doxorubicin. However, this type of doxorubicin liposomes are difficult to release in tumor tissues, and doxorubicin is not easy to enter tumor cells to exert a killing effect. Clinically, it has also been found that doxil liposomes may cause allergic reactions, which may be related to the non-spherical shape of the liposomes caused by doxorubicin precipitation in the aqueous phase of the liposomes (Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine. 2012 Feb; 8(2): 176-84).

[0004] In the presence of ionophores, liposomes with metal ion gradients can also effectively load weakly basic molecules remotely (U.S. Pat. No. 5,837,282, Ionophore-mediated liposome loading; Biochim. Biophys. Acta (1998) 1414: 188-204). 2+Gradient sphingomyelin / cholesterol liposomes can be remotely loaded with doxorubicin (Biochimica et Biophysica Acta. 1998, 1414: 205), Mn 2+ Form a complex with doxorubicin in the aqueous phase within the liposome. Liposomes with other transition metal ion gradients can also remotely load doxorubicin and other weakly alkaline chemotherapeutic drugs (US Pat. No. 7,744,921, Copper-Doxorubicin as a Nanoparticle Cargo Retains Efficacy with Minimal Toxicity. Mol Pharm. 2010, 7 (6): 1948-58). However, liposomes containing transition metal ions in the aqueous phase are prone to hydrolysis and precipitation of transition metal ions during the manufacturing process, especially in the presence of a heating step, resulting in poor stability of the obtained liposomes. Moreover, transition metal ion salt solutions are also prone to corroding metal equipment during the preparation of liposomes. Adding a complexing agent, triethanolamine, can inhibit this hydrolysis and corrosion. Triethanolamine is an acceptable but limited component in drug manufacturing. Although many studies have shown that transition metal ion gradient liposomes can provide satisfactory anthraquinone drug loading rates, liposome transition metal ion-drug complexes may additionally produce complex drug biological functions, affecting clinical transformation.

[0005] In addition, the extracellular microenvironment of many tumors has a lower pH than that of blood and normal tissues, and the lysosomes in tumor cells are more acidic, which makes it possible to use pH-responsive release function to enhance the therapeutic effect of liposome drugs on tumors. Many studies have used the addition of chemical molecules that are sensitive to acidic environments and can cause damage to the lipid layer structure and leakage to construct pH-responsive release liposome drugs. However, this type of liposome drugs often have good stability in vitro, but most are unstable in vivo. Summary of the invention

[0006] In view of this, the technical problem to be solved by the present invention is to provide a chemotherapy drug liposome that can effectively encapsulate weakly alkaline anthraquinone drugs and has a tumor acidic microenvironment responsive release function and a preparation method thereof.

[0007] The present invention provides a method for preparing chemotherapeutic drug liposomes, comprising the following steps:

[0008] S1) preparing liposomes with a weak salt gradient of magnesium ions;

[0009] S2) mixing the liposomes having a magnesium ion weak salt gradient with an aqueous solution of anthraquinone drug molecules, heating, and purifying to obtain chemotherapeutic drug liposomes.

[0010] Preferably, the step S1) is specifically:

[0011] A1) mixing lipid components in an organic solvent and removing the solvent to obtain a lipid film; the lipid components include phospholipid compounds and cholesterol;

[0012] A2) hydrating the lipid film with an aqueous medium containing a weak salt of magnesium ions to obtain a liposome suspension;

[0013] A3) subjecting the liposome suspension to nano-treatment to obtain nano-liposomes;

[0014] A4) replacing the external aqueous phase of the nanoliposome with a solution containing no magnesium ion weak salt, to obtain liposomes with a magnesium ion weak salt gradient.

[0015] Preferably, the phospholipid compound includes one or more of natural phospholipids, hydrogenated phospholipids, synthetic phospholipids, phospholipid-polyethylene glycol, phospholipid-polyethylene glycol-folic acid derivatives and other phospholipid-polyethylene glycol-tumor specific targeting molecule derivatives;

[0016] The molar concentration of cholesterol in the lipid component is 20% to 45%;

[0017] The organic solvent is selected from one or more of chloroform, ethanol and isopropanol.

[0018] Preferably, the weak acid in the magnesium ion weak salt is selected from organic acids and / or organic hydrochlorides; the organic acid is selected from one or more of acetic acid, propionic acid, butyric acid, fumaric acid, maleic acid, gluconic acid, ascorbic acid, 4-hydroxyethylpiperazineethanesulfonic acid, 3-morpholinepropanesulfonic acid, aspartic acid and malonic acid; the organic hydrochloride is selected from one or more of tris(hydroxymethyl)aminomethane hydrochloride and / or triethylamine hydrochloride;

[0019] The concentration of magnesium ions in the aqueous medium containing the magnesium ion weak acid salt is 0.15-1 mol / L.

[0020] Preferably, the particle size of the nanoliposome is 50 to 200 nm.

[0021] Preferably, in step S4), the external aqueous phase of the nanoliposomes is replaced with a solution of a weak acid salt containing no magnesium ions by one or more treatments selected from column exchange, dialysis and ultrafiltration; the solution of a weak acid salt containing no magnesium ions is selected from sodium chloride solution, glucose solution or pH buffer solution.

[0022] Preferably, the molar ratio of total lipids to anthraquinone drug molecules in the liposomes having a magnesium ion weak salt gradient in step S2) is 1:(0.1-0.5).

[0023] Preferably, after mixing in step S2), an alkaline solution is added to adjust the pH value of the system to 7.4 to 8.5;

[0024] And / or, the heating temperature in step S2) is 50° C. to 60° C.; the heating time is 5 to 15 minutes.

[0025] The present invention also provides a chemotherapeutic drug liposome prepared by the above preparation method.

[0026] The present invention also provides an application of the chemotherapy drug liposome prepared by the above preparation method in preparing drugs for treating tumors.

[0027] The present invention provides a method for preparing chemotherapeutic drug liposomes, comprising the following steps: S1) preparing liposomes with a magnesium ion weak salt gradient; S2) mixing the liposomes with a magnesium ion weak salt gradient with an aqueous solution of anthraquinone drug molecules, heating, and purifying to obtain the chemotherapeutic drug liposomes. Compared with the prior art, the present invention utilizes liposomes containing magnesium ion weak salt in the inner water phase to effectively achieve remote loading of weakly alkaline anthraquinone drug molecules by the magnesium ion weak salt gradient method. 2+ It can form a complex with anthraquinone drug molecules, and its stability is affected by pH. Under physiological weak alkaline conditions, the complex is stable in the presence of high concentrations of Mg 2+ However, when the pH of the solution drops to acidic, the complex dissociates, causing the drug molecules to be easily released from the liposomes and enter the external aqueous phase solution, so that the obtained chemotherapy drug liposomes can not only effectively encapsulate anthraquinone drugs, but also the chemotherapy drug liposomes encapsulating magnesium ion anthraquinone drugs are stable under physiological weak alkaline conditions, but can slowly release drugs in the acidic microenvironment of the tumor, and have the function of responsive release to the acidic microenvironment of the tumor, which can increase the uptake of drug molecules in tumor cells, improve the efficacy of tumor chemotherapy, and meet the needs of intratumoral delivery and release of chemotherapy drugs in tumor treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 Schematic diagram of remote loading of anthraquinone drugs by liposomes with a weak salt gradient of magnesium ions;

[0029] Figure 2 The UV-visible absorption spectra of the complex formed by doxorubicin and magnesium salts of different concentrations in pH 7.8 HEPES buffer;

[0030] Figure 3 The UV-visible absorption spectra of doxorubicin / MgAc2 mixed solutions under different pH conditions;

[0031] Figure 4 is the release curve of Mg-doxorubicin liposome drug;

[0032] Figure 5 Microscopic fluorescence imaging of doxorubicin uptake by tumor cells;

[0033] Figure 6 This is a graph showing the effect of doxorubicin liposomes on the proliferation activity of tumor cells;

[0034] Figure 7 This is a diagram showing the inhibitory effect of doxorubicin liposome drug on the growth of breast cancer transplanted tumors in mice. DETAILED DESCRIPTION

[0035] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0036] The invention provides a method for preparing chemotherapeutic drug liposomes, comprising the following steps: S1) preparing liposomes with a magnesium ion weak salt gradient; S2) mixing the liposomes with the magnesium ion weak salt gradient with an aqueous solution of anthraquinone drug molecules, heating, and purifying to obtain the chemotherapeutic drug liposomes.

[0037] See also Figure 1 , Figure 1 Schematic diagram of remote loading of anthraquinone drugs into liposomes with a weak magnesium ion salt gradient.

[0038] In the present invention, liposomes with a magnesium ion weak acid salt gradient are first prepared, wherein the inner aqueous phase of the liposomes with a magnesium ion weak acid salt gradient contains magnesium ion weak acid salt, while the outer aqueous phase does not contain magnesium ion weak acid salt, wherein the concentration of magnesium ions in the inner aqueous phase is preferably 0.15 to 1 mol / L, more preferably 0.15 to 0.5 mol / L, and even more preferably 0.25 to 0.5 mol / L; in some embodiments provided by the present invention, the concentration of magnesium ions in the inner aqueous phase is specifically 0.15 mol / L, 0.3 mol / L, ol / L or 0.5mol / L; the weak acid in the magnesium ion weak salt is preferably an organic acid and / or an organic hydrochloride; the organic acid is preferably a monocarboxylic acid and / or a dicarboxylic acid, more preferably one or more of acetic acid, propionic acid, butyric acid, fumaric acid, maleic acid, gluconic acid, ascorbic acid, 4-hydroxyethylpiperazineethanesulfonic acid, 3-morpholinepropanesulfonic acid, aspartic acid and malonic acid; the organic hydrochloride is preferably one or two of tris(hydroxymethyl)aminomethane hydrochloride and triethylamine hydrochloride; the magnesium ion weak salt gradient The particle size of the liposomes is preferably nanometer-scale, more preferably 50-200nm, more preferably 50-150nm, and most preferably 80-120nm; the polydispersity index of the liposomes with a magnesium ion weak acid salt gradient is less than 0.25; the lipid components used in the liposomes are lipid molecules that are well known to those skilled in the art and can be used to form stable liposomes, such as various phospholipid molecules and cholesterol, and components for prolonging the circulation time of the liposomes in the body, such as phospholipid-PEG amphiphilic polymers, can be added, and chemical groups with specific targeting to tumors, such as phospholipid-PEG folic acid derivatives, can also be added to enhance the targeting effect of the liposomes on tumors; the liposomes containing magnesium ion weak acid salts in the inner aqueous phase are in an aqueous phase medium, i.e., an outer aqueous phase; the outer aqueous phase is a solution without magnesium ion weak acid salts, so that there is a magnesium ion gradient between the inner aqueous phase and the outer aqueous phase of the liposomes; the outer aqueous phase is preferably a sodium chloride solution, a glucose solution or a pH buffer solution; in some embodiments provided by the present invention, the outer aqueous phase can specifically be a physiological saline.

[0039] The liposomes with a magnesium ion weak salt gradient described in the present invention can be prepared according to methods well known to those skilled in the art, such as a thin film hydration method, without any special restrictions. The present invention is preferably specifically as follows: A1) mixing lipid components in an organic solvent, removing the solvent, and obtaining a lipid film; the lipid components include phospholipid compounds and cholesterol; A2) hydrating the lipid film with an aqueous medium containing a magnesium ion weak salt to obtain a liposome suspension; A3) subjecting the liposome suspension to nano-treatment to obtain nano-liposomes; A4) replacing the external aqueous phase of the nano-liposomes with a solution not containing a magnesium ion weak salt to obtain a liposome with a magnesium ion weak salt gradient.

[0040] In a specific embodiment provided by the present invention, the phospholipid compound preferably includes one or more of natural phospholipids, hydrogenated phospholipids, synthetic phospholipids, phospholipid-polyethylene glycol, phospholipid-polyethylene glycol-folic acid derivatives and other phospholipid-polyethylene glycol-tumor-specific targeting molecule derivatives.

[0041] In a specific embodiment provided by the present invention, the phospholipid compound includes distearoylphosphatidylcholine; more specifically, in addition to distearoylphosphatidylcholine, a small amount of phospholipid-polyethylene glycol compounds can also be added; the phospholipid-polyethylene glycol compounds are preferably distearoylphosphatidylethanolamine-polyethylene glycol and / or distearoylphosphatidylethanolamine-polyethylene glycol-folic acid.

[0042] In a specific embodiment provided by the present invention, the molar concentration of the phospholipid-polyethylene glycol compound in the lipid component is preferably 5% to 15%.

[0043] In a specific embodiment provided by the present invention, the molar concentration of cholesterol in the lipid component is 20% to 45%.

[0044] Phospholipid compounds and cholesterol are dissolved in an organic solvent, and the solvent is removed to obtain a lipid film; the organic solvent can be any organic solvent well known to those skilled in the art without any special restrictions, and in the present invention, it is preferably one or more of chloroform, ethanol and isopropanol; the method for removing the solvent can be any method well known to those skilled in the art without any special restrictions, and in the present invention, the solvent is preferably removed by reduced pressure distillation; the temperature of the reduced pressure distillation is preferably 50°C to 70°C, more preferably 55°C to 65°C; after removing the solvent, it is preferably vacuum dried to obtain a lipid film.

[0045] The lipid film is hydrated with an aqueous medium containing a magnesium ion weak salt to obtain a liposome suspension; the weak acid in the magnesium ion weak salt is preferably an organic acid and / or an organic hydrochloride; the organic acid is preferably a monobasic acid and / or an organic dibasic acid, more preferably one or more of acetic acid, propionic acid, butyric acid, fumaric acid, maleic acid, gluconic acid, ascorbic acid, 4-hydroxyethylpiperazineethanesulfonic acid, 3-morpholinepropanesulfonic acid, aspartic acid and malonic acid; the organic hydrochloride is selected from one or two of tris(hydroxymethyl)aminomethane hydrochloride and / or triethylamine hydrochloride; the concentration of magnesium ions in the aqueous medium containing ... dibasic acid, more preferably one or more of acetic acid, propionic acid, butyric acid, fumaric acid, maleic acid, gluconic acid, ascorbic acid, 4-hydroxyethylpiperazineethanesulfonic acid, 3-morpholinepropanesulfonic acid, aspartic acid and malonic acid; the organic hydrochloride is selected from one or two of tris(hydroxymethyl)aminomethane hydrochloride and / or triethylamine hydrochloride; the concentration of magnesium ions in the aqueous medium containing the magnesium ion weak salt is preferably an organic acid and / or an organic dibasic The concentration of magnesium ions in the aqueous medium containing a magnesium ion weak salt is 0.15-1 mol / L, more preferably 0.15-0.5 mol / L, and even more preferably 0.25-0.5 mol / L; in some embodiments provided by the present invention, the concentration of magnesium ions in the aqueous medium containing a magnesium ion weak salt is specifically 0.15 mol / L, 0.3 mol / L or 0.5 mol / L; the ratio of the lipid film to the aqueous medium containing a magnesium ion weak salt is preferably (50-100) mg: 2 mL; after hydration, it is preferably subjected to one or more of heating, oscillation and ultrasonic treatment to obtain a liposome suspension; the heating temperature is preferably 55°C-65°C.

[0046] The liposome suspension is subjected to nano-treatment to obtain nano-liposomes; the method of the nano-treatment is a method well known to those skilled in the art and is not particularly limited. In the present invention, extrusion or homogenization is preferably used; the extrusion is preferably carried out using a nano-nuclear pore membrane, and more preferably, nano-nuclear pore membranes with different pore sizes from large to small are used in sequence; the homogenization is preferably carried out using a high-pressure homogenization; the particle size of the nano-liposome is preferably 50 to 200 nm, more preferably 50 to 150 nm, and even more preferably 80 to 120 nm; the polydispersity index of the nano-liposome is less than 0.25.

[0047] The external aqueous phase of the nanoliposome is replaced with a solution containing no magnesium ion weak acid salt to obtain liposomes with a magnesium ion weak acid salt gradient; in the present invention, the external aqueous phase of the nanoliposome is preferably replaced with a solution containing no magnesium ion weak acid salt by one or more treatments selected from column exchange, dialysis and ultrafiltration; in some embodiments provided by the present invention, the external aqueous phase of the nanoliposome is replaced with a solution containing no magnesium ion weak acid salt by column exchange; the column exchange is preferably carried out using a desalting column, more preferably a PD10 gel desalting column; the solution containing no magnesium ion weak acid salt is preferably a sodium chloride solution, a glucose solution or a pH buffer solution; in some embodiments provided by the present invention, the solution containing no magnesium ion weak acid salt is specifically physiological saline.

[0048] The liposomes with a magnesium ion weak acid salt gradient are mixed with an aqueous solution of anthraquinone drug molecules, heated, and purified to obtain chemotherapy drug liposomes; the anthraquinone drug molecules can be anthraquinone drugs well known to those skilled in the art, without special restrictions, and are preferably one or more of doxorubicin, epirubicin and daunomycin in the present invention; the molar ratio of total lipids to anthraquinone drug molecules in the liposomes with a magnesium ion weak acid salt gradient is preferably 1:(0.1-0.5), more preferably 1:(0.125-0.5), and even more preferably 1:(0.15-0.5); in some embodiments provided by the present invention, the molar ratio of total lipids to anthraquinone drug molecules in the liposomes with a magnesium ion weak acid salt gradient is specifically 1:0.16; the heating temperature is preferably 50°C-60°C, more preferably 55°C-60°C; the heating time is preferably 5-15 min, more preferably 5-10 min.

[0049] In a specific embodiment provided by the present invention, the liposomes with a magnesium ion weak salt gradient are mixed with an aqueous solution of anthraquinone drug molecules, an alkaline solution is added to provide the pH value of the system to a weak alkaline state, heated, and purified to obtain chemotherapy drug liposomes; preferably, an alkaline solution is added to adjust the pH value of the system to 7.4-8.5; the alkaline solution is one or more of a sodium bicarbonate solution, a sodium carbonate solution, and a HEPES buffer solution, preferably a sodium bicarbonate solution; in some embodiments provided by the present invention, the concentration of sodium bicarbonate in the alkaline solution in the system is preferably 100-150 mM, more preferably 125 mM. When the mixed system is heated at a temperature higher than the phase transition temperature of the liposome, the color of the solution changes significantly as can be seen by the naked eye, and the weakly alkaline drug molecules in the aqueous phase outside the liposomes cross the membrane into the liposomes and react with the Mg in the aqueous phase inside. 2+ Complexation occurs, and the liposomes are remotely loaded with anthraquinone drug molecules. When the drug-lipid molar ratio is 0.15-0.5, the drug encapsulation rate can reach more than 90%, and under the optimal conditions, the drug encapsulation rate can be close to 100%.

[0050] In another specific embodiment provided by the present invention, after heating, purification is performed to obtain chemotherapeutic drug liposomes; the purification method is a method well known to those skilled in the art and is not particularly limited. In the present invention, it is preferred to use gel column separation, dialysis or ultrafiltration for purification; the unencapsulated free anthraquinone drug molecules can be removed by purification to obtain chemotherapeutic drug liposomes; in some embodiments provided by the present invention, gel column separation is specifically used for purification, and PD-10 desalting column separation and purification is more preferably used; the eluent used for purification is preferably phosphate buffered saline solution, HEPES buffered saline solution, or sodium chloride saline solution containing sodium bicarbonate; the concentration of sodium bicarbonate in the saline solution containing sodium bicarbonate is preferably 5-25 mmol / L; the chemotherapeutic drug liposomes are preferably stored in a weakly alkaline solution, such as phosphate buffered saline solution, HEPES buffered saline solution, or sodium chloride saline solution containing sodium bicarbonate.

[0051] In another specific embodiment provided by the present invention, the concentration of the chemotherapeutic drug liposomes can be further adjusted, filtered and sterilized through a sterile filter membrane, and filled into a medicinal vial to obtain a drug injection of the chemotherapeutic drug liposomes. It is also possible to add a lyophilization protectant to the sample of the chemotherapeutic drug liposomes, adjust the drug concentration, filter and sterilize, fill in a bottle, and freeze-dry to obtain a lyophilized powder.

[0052] The present invention utilizes liposomes containing magnesium ion weak salt in the inner water phase to effectively achieve remote loading of weakly basic anthraquinone drug molecules by the magnesium ion weak salt gradient method. 2+ It can form a complex with anthraquinone drug molecules, and its stability is affected by pH. Under physiological weak alkaline conditions, the complex is stable in the presence of high concentrations of Mg 2+ However, when the pH of the solution drops to acidic, the complex dissociates, causing the drug molecules to be easily released from the liposomes and enter the external aqueous phase solution, so that the obtained chemotherapy drug liposomes can not only effectively encapsulate weakly alkaline anthraquinone drugs, but also the chemotherapy drug liposomes encapsulating magnesium ion anthraquinone drugs are stable under physiological weakly alkaline conditions, but can slowly release drugs in the acidic microenvironment of the tumor, and have the function of responsive release to the acidic microenvironment of the tumor, which can increase the uptake of drug molecules in tumor cells, improve the efficacy of tumor chemotherapy, and meet the needs of intratumoral delivery and release of chemotherapy drugs in tumor treatment.

[0053] The present invention also provides a chemotherapeutic drug liposome prepared by the above preparation method; the inner water phase of the chemotherapeutic drug liposome contains Mg 2+ Complexes with anthraquinone drug molecules.

[0054] The present invention also provides an application of the chemotherapy drug liposome prepared by the above preparation method in preparing drugs for treating tumors.

[0055] In order to further illustrate the present invention, a chemotherapeutic drug liposome and a preparation method thereof provided by the present invention are described in detail below in conjunction with examples.

[0056] The reagents used in the following examples are all commercially available.

[0057] Example 1

[0058] Determination of different Mg 2+ UV-visible absorption spectrum and fluorescence spectrum of doxorubicin solution under concentration conditions. Use 100mM HEPES, pH 7.8 buffer as solvent to prepare a mixed solution containing 0.144mM doxorubicin hydrochloride and different concentrations of magnesium sulfate (0-500mM). Take 180uL of each sample and add it to a 96-well plate. Use a multifunctional microplate reader to measure the UV-visible absorption spectrum and fluorescence spectrum to obtain the UV-visible absorption spectrum of the complex formed by doxorubicin and different concentrations of magnesium salt in pH 7.8 HEPES buffer. Figure 2 As shown. Figure 2 It can be seen that under weak alkaline conditions, with Mg 2+ With the increase of Mg concentration, the visible light absorption spectrum of doxorubicin changed significantly. The broad absorption band at 480-500 nm gradually weakened, and the absorption band at Mg concentration increased significantly. 2+ As the concentration increases, a red shift occurs, and the shoulder peak at 538 nm gradually becomes the strongest peak. A new characteristic absorption band appears at 580 nm, which is attributed to the formation of Mg-doxorubicin complex. 2+ The ion concentration was close to saturation at 200 mM, indicating that doxorubicin was almost completely converted into Mg-doxorubicin complex.

[0059] With Mg 2+ With the increase of concentration, the fluorescence spectrum of doxorubicin also changes significantly. 2+ The addition of Mg resulted in a red shift in the Ex480nm / Em595nm fluorescence band of doxorubicin and the generation of two new fluorescence bands at Ex540nm / Em605nm and Ex580nm / Em640nm, which can be attributed to the Mg-doxorubicin complex. 2+ The concentration increases rapidly, and in Mg 2+ The maximum value was reached at a concentration of 150 mM.

[0060] Example 2

[0061] Determine the visible light absorption spectrum and fluorescence spectrum of the mixed solution of magnesium salt and doxorubicin under different pH conditions. Prepare a mixed solution of 500mM magnesium acetate and a certain concentration of doxorubicin, adjust the pH value with dilute hydrochloric acid or HEPES buffer, and measure the pH value of the mixed solution with a digital pH meter (the pH range is 5.25-8.24; the weak acid solution with pH <7 is adjusted with 1M hydrochloric acid, and the weak alkaline solution with pH >7 is adjusted with HEPES buffer). It can be seen with the naked eye that as the pH increases, the color of the solution undergoes a transition from orange-yellow to purple-red. The UV-visible absorption spectra of 44.6μM doxorubicin / 500mM MgAc2 mixed solutions with different pH values ​​were measured with an enzyme marker, as shown in Figure 2. Figure 3 The results show that at pH 5.25, the spectrum is similar to that without Mg 2+ The situation of doxorubicin solution with MgCl2 and pH 7.8 was similar. However, when the pH was increased to 6.0, the absorption intensity of the absorption band at 480 nm increased, the shoulder peak at 538 nm became more obvious, and a new peak appeared at 580 nm, indicating that MgCl2 2+ Complexation reaction occurred with doxorubicin. When the pH continued to rise, the absorption peak intensities at 538nm and 580nm gradually increased, reflecting the increase in the degree of complexation reaction.

[0062] Example 3 Preparation of blank liposomes

[0063] Blank liposomes were prepared by thin film hydration method and nucleoporation membrane extrusion method. 61.6 mg of distearoylphosphatidylcholine (DSPC) and 16.2 mg of cholesterol (Chol) (molar ratio of 65:35) were weighed and placed in a round-bottom flask, 10 mL of chloroform was added to dissolve, heated at 60 ° C and distilled under reduced pressure, and the obtained lipid film was vacuum dried, and then 2 mL of 500 mM MgAc2 aqueous solution was added for hydration, heated at 60 ° C ~ 65 ° C in a water bath and ultrasonically treated with an ultrasonic cleaner to obtain a suspension. Under the condition of keeping warm at 65 ° C, the suspension was sequentially extruded by a liposome extruder through 800, 600, 400, 200 and 100 nm nucleoporation membranes to obtain DSPC / Chol liposomes containing MgAc2 of corresponding particle sizes.

[0064] 56.9 mg DSPC, 16.2 mg Chol and 16.8 mg distearoylphosphatidylethanolamine-polyethylene glycol 2000 (DSPE-PEG2000) (molar ratio of 60:35:5) were weighed and placed in a round-bottom flask, 15 ml of anhydrous ethanol was added to dissolve, heated at 60°C for reduced pressure distillation and the obtained lipid film was vacuum dried, then 2 mL of 150 mM, 300 mM or 500 mM MgAc2 aqueous solution was added for hydration, heated at 65°C in a water bath and ultrasonicated to obtain a suspension. Under the condition of keeping warm at 65°C, the suspension was successively extruded by a liposome extruder through 400 and 100 nm nuclear pore membranes to obtain DSPC / Chol / DSPE-PEG2000 liposomes containing MgAc2 with a particle size of about 100 nm.

[0065] 52.0 mg DSPC, 17.3 mg Chol, 10.4 mg DSPE-PEG2000 and 6.9 mg distearoylphosphatidylethanolamine-polyethylene glycol 2000-folic acid (DSPE-PEG2000-FA) (molar ratio of 55:37:3:2) were weighed and placed in a round-bottom flask, anhydrous ethanol was added to dissolve, heated at 60°C and distilled under reduced pressure, and the obtained lipid film was vacuum dried, and then 2 mL 300 mM MgAc2 aqueous solution was added for hydration, heated at 65°C in a water bath and ultrasonicated to obtain a suspension. Under the condition of keeping warm at 65°C, the suspension was successively extruded by a liposome extruder through 400 and 100 nm nuclear pore membranes to obtain DSPC / CH / PE-PEG2000 / PE-PEG2000-FA liposomes containing MgAc2 and targeting folic acid receptors with a particle size of about 100 nm.

[0066] The hydration kinetics size of the liposome nanoparticles was determined by dynamic light scattering. The particle sizes of the liposomes extruded through a 100 nm pore size nuclear pore membrane were all close to 100 nm, and the polydispersity index was all <0.25.

[0067] Example 4 Liposome remote loading of doxorubicin drug

[0068] The 100nm blank MgAc2 liposomes (DSPC / Chol / DSPE-PEG2000 liposomes containing MgAc2) obtained in Example 3 were purified with a PD10 gel desalting column, eluted with normal saline, and the liposome components that flowed out were collected. The liposomes whose external aqueous phase was normal saline were mixed with an aqueous solution of doxorubicin hydrochloride at a molar ratio of doxorubicin / total lipids in the liposomes (D / TLs) of 0.125-0.5, and the solution was adjusted to a weak alkaline (pH value 7.4-8.5) with sodium bicarbonate, sodium carbonate, or HEPES buffer. The liposomes with a D / TLs of 0.16 and a mixed system of doxorubicin (containing 125mM NaHCO3) were placed in a 50°C, 55°C, or 60°C water bath, respectively. It can be seen that the color of the solution gradually changes to purple-red, especially at 55°C and 60°C, the color changes more rapidly, and becomes purple-red after 5min. Continue heating, the solution remains stable, and no obvious precipitation occurs within 6h. The liposomes were separated and purified by PD-10 gel desalting column after heating at 55℃ and 60℃ for 5-10min. The eluent was 10mM NaHCO3 / normal saline, and the purple-red doxorubicin liposome fraction was collected. 150mM hydrochloric acid / isopropanol (HCl / IPA) solution was added to the purified doxorubicin liposome sample at a volume ratio of 1:2. After shaking and standing for 15min, the absorbance at 480nm was measured and the concentration of doxorubicin was calculated. The results showed that the encapsulation efficiency of MgAc2 liposomes for doxorubicin was >85%, and the encapsulation efficiency of liposomes containing 300mM or 500mM high concentration MgAc2 in the inner aqueous phase was close to 100%. The particle size of the obtained Mg-doxorubicin liposomes was measured by dynamic light scattering method, which was close to 100nm, similar to the corresponding blank liposomes.

[0069] After the reaction mixture of blank liposomes remotely loaded with doxorubicin under different conditions was diluted with the corresponding medium, samples were placed in a 96-well plate and the visible light absorption spectrum and fluorescence spectrum were measured by a microplate reader. The results showed that when NaHCO3 and HEPES pH7.4-8.0 buffer were added to the reaction system, the 480nm visible light absorption band of doxorubicin in the solution was red-shifted after heating, and the Ex480 / Em595 fluorescence emission intensity rapidly weakened with the extension of heating time. The higher the pH of the reaction system, the faster the decay of the fluorescence band after heating. The visible light absorption spectrum and fluorescence spectrum during the remote drug loading process reflect that MgAc2 gradient liposomes can quickly and efficiently load doxorubicin under alkaline and heating conditions, and doxorubicin and Mg in the aqueous phase of the liposomes can be loaded with doxorubicin quickly and efficiently. 2+ The complex formed by the ions rapidly undergoes fluorescence quenching as the concentration increases.

[0070] Example 5 MgAc2 liposomes remotely loaded with epirubicin hydrochloride and daunomycin hydrochloride

[0071] Epirubicin hydrochloride and daunomycin hydrochloride were mixed with 300mM MgAc2 gradient DSPC / Chol / DSPE-PEG2000 liposomes prepared in Example 3 at a drug-lipid molar ratio of 0.16:1, 125mM NaHCO3 was added, heated in a 55°C water bath for 5-10 minutes, cooled to room temperature, separated and purified with a PD-10 desalting column, and the eluent was 10mM NaHCO3 / normal saline. The purple-red drug-loaded liposome components were collected and the concentration of epirubicin or daunomycin hydrochloride in the liposomes was determined. The results showed that the encapsulation rate of MgAc2 liposomes for epirubicin and daunomycin was >90%. The particle sizes of blank MgAc2 liposomes, Mg-epirerubicin liposomes and Mg-daunomycin liposomes were all close to 100nm measured by dynamic light scattering, and there was no obvious change before and after drug loading.

[0072] Experimental Example 6 Liposome drug release experiment

[0073] The drug release properties of 100 nm Mg-doxorubicin DSPC / Chol / DSPE-PEG2000 liposomes purified by PD10 desalting column in different pH environments were measured by dialysis analysis. 2 mL of purified liposomes (containing 1.44 mM doxorubicin and 9 mM total lipids in the liposomes) were placed in three dialysis bags with a molecular weight cutoff of 50 kDa, and the dialysis bags were immersed in 90 mL of three different acidity dialysates, 10 mM acetic acid-sodium acetate buffer / normal saline (pH 5.5), 5 mM NaHCO3 / normal saline (pH 7.4) and normal saline containing 10% serum (pH 7.0). Stir at 37 ± 0.5 ° C. At different time points (1, 2, 3, 6, 12, 24, 36, 48 h), 1 mL of dialysate was drawn and supplemented with the same volume of dissolution medium. 150 mM HCl / IPA was added to the sample at a volume ratio of 1:2, and the fluorescence intensity of doxorubicin at Ex480nm / Em590nm was measured using a microplate reader. The ratio of doxorubicin released from the liposomes into the dialysate was calculated to obtain the release curves of Mg-doxorubicin liposomes in different pH solutions, as shown in Fig. Figure 4 As shown. Figure 4 It can be seen that both Mg-doxorubicin liposomes and folate receptor-targeted Mg-doxorubicin liposomes are relatively stable in weakly alkaline buffers. When the pH of the medium decreases, the release of doxorubicin increases. In saline containing 10% serum, the release rate is relatively slow, and the release rate is about 30% by 48h. In pH 5.5 buffer, it presents two stages, fast and slow, with about 60% of doxorubicin being released quickly within 12h, and then the release becomes slower. These results reflect the release properties of Mg-doxorubicin liposomes in response to the acidic environment of tumors.

[0074] Example 7 Experiment on the uptake of liposome drugs by tumor cells

[0075] Take a 13 mm round glass slide, sterilize and dry it, and place it on the bottom of a 24-well plate. Then, place 5 × 10 4 The cultured human breast cancer MDA-MB-231 cell suspension was added to a 24-well plate with a glass slide, and transferred to an incubator overnight to allow the cells to adhere to the wall. On the second day, doxorubicin hydrochloride with a doxorubicin concentration of 10 μg / mL, the above-mentioned Mg-doxorubicin DSPC / Chol / DSPE-PEG2000 liposomes (MgAc2 concentration of 300 mM, D / TLs ratio of 0.16) or Mg-doxorubicin DSPC / Chol / DSPE-PEG2000 / DSPE-PEG2000-FA liposomes (MgAc2 concentration of 300 mM, D / TLs molar ratio of 0.16) were added to each well, and 3 replicate wells were set for each group. After incubation in the incubator for 3 hours, the cells were washed twice with PBS, fixed with 4% paraformaldehyde, washed twice with PBS, removed, and transferred to a clean slide with DAPI added to the nucleus stain. The cells were observed and photographed under a fluorescence microscope to obtain a microscopic fluorescence image of breast cancer MDA-MB-231 cells taking up doxorubicin. Figure 5 As shown, the top is doxorubicin hydrochloride, the middle is Mg-doxorubicin DSPC / Chol / DSPE-PEG2000 liposomes, and the bottom is Mg-doxorubicin DSPC / Chol / DSPE-PEG2000 / DSPE-PEG2000-FA liposomes. Figure 5 The results showed that a strong doxorubicin fluorescence signal was soon detected in the tumor cell nuclei of the doxorubicin hydrochloride group after administration, while only a weak doxorubicin fluorescence signal was detected in the tumor cells of the Mg-doxorubicin liposome group within 12 hours after administration. An obvious doxorubicin fluorescence signal was also detected in the tumor cell nuclei of the Mg-doxorubicin folate receptor targeted liposome group after administration, but the intensity was weaker than that of the doxorubicin hydrochloride group.

[0076] Example 8 Toxicity experiment of liposome drugs on tumor cells

[0077] Dilute the digested and counted MCF-7 and MDA-MB-231 cells in the logarithmic growth phase to 6×10 4Cells / mL. Add to a 96-well plate, add 100 μL Gibco DMEM medium (Thermo Fisher Scientific (China) Co., Ltd.) to each well, and culture until the cells adhere to the wall. Add 100 μL of doxorubicin hydrochloride solution diluted with DMEM medium, Doxil-like ammonium sulfate gradient doxorubicin liposomes (prepared by the laboratory with reference to the Doxil formula) and Mg-doxorubicin DSPC / Chol / DSPE-PEG2000 liposome solution (preparation method see Example 4, MgAc2 concentration 300mM, D / TLs ratio of 0.16) (doxorubicin concentration of 0.108-110.3 μM) to the well plate, add an equal volume of DMEM medium to the control group, incubate with tumor cells for a period of time, remove the culture medium in the 96-well plate, and wash twice. CCK8 and culture medium are configured in a ratio of 10 μL: 100 μL, and 100 μL of culture medium containing CCK8 is added to each well of the 96-well plate. Continue to incubate in the cell culture incubator for 2 hours, use a multifunctional microplate reader to detect the OD value at 450nm, calculate the average cell viability, and obtain the effect of doxorubicin on the proliferation activity of tumor cells. Figure 6 As shown, Figure 6 The middle left is MCF-7 cells, and the right is MDA-MB-231 cells.

[0078] Figure 6 The results showed that after the tumor cells were treated with different doxorubicin preparations for 48 hours, the anti-tumor cell proliferation ability of Mg-doxorubicin liposomes was significantly lower than that of free doxorubicin, but stronger than that of ammonium sulfate gradient doxorubicin liposomes, which was consistent with the sustained release properties of Mg-doxorubicin liposomes. The cell viability-drug concentration curve was fitted using GraphPad Prism 8.0, and the IC50 values ​​of Mg-doxorubicin DSPC / Chol / DSPE-PEG2000 liposomes in killing MCF-7 cells and MDA-MB-231 were 0.86±0.31μM and 0.22±0.09μM, respectively.

[0079] Example 9 Therapeutic effect of liposome drugs on breast cancer-bearing mice

[0080] Mouse breast cancer EO771 cells were cultured in DMEM medium containing 10% FBS and 1% penicillin-streptomycin at 37°C in an incubator with an atmosphere of 5% CO2. EO771 cells cultured in vitro at nearly 90% confluence were digested with trypsin-EDTA solution, centrifuged and resuspended in PBS. 0.2 ml of PBS suspension containing 200,000 EO771 cells was inoculated into the subcutaneous mammary gland near the left lower limb of 6-8 week old female C57BL / 6 mice. The size of palpable tumors was measured with a digital caliper. The tumor volume (V) was calculated as V = L × W × W / 2, where L and W represent the maximum length and width perpendicular to the maximum length of the tumor, respectively. Twenty-four tumor-bearing mice were randomly divided into four groups, including a non-administered control group, a 100 nm ammonium sulfate doxorubicin liposome group, a 100 nm Mg-doxorubicin DSPC / Chol / DSPE-PEG2000 liposome group (MgAc2 concentration of 300 mM, D / TLs ratio of 0.16), and a folic acid-targeted Mg-doxorubicin DSPC / Chol / DSPE-PEG2000 / DSPE-PEG2000-FA liposome group (MgAc2 concentration of 300 mM, D / TLs molar ratio of 0.16) (6 mice in each group). Each mouse in the experimental group was injected with a liposome drug equivalent to a doxorubicin dose of 5 mg / kg body weight through the tail vein on days 0, 4, 8, and 12 (the injection solvent was a sodium chloride saline solution containing 10 mM sodium bicarbonate). Body weight and tumor size were measured every two days. The results showed that there was no significant difference in mouse body weight between groups during the experiment. However, the tumor size was Figure 7 As shown in the figure, from the 8th to the 16th day after administration, the tumor volume of the control group mice increased rapidly, while the tumor volume of the Mg-doxorubicin liposome group, the folic acid-targeted Mg-doxorubicin liposome group and the ammonium sulfate-doxorubicin liposome group mice also increased, but was significantly lower than the control group on the 14th and 16th days; there was no significant difference in tumor volume between the two groups of the three groups of doxorubicin liposomes, indicating that the inhibitory effect of Mg-doxorubicin liposomes and folic acid-targeted Mg-doxorubicin liposomes on tumor growth under experimental conditions was not weaker than that of ammonium sulfate-doxorubicin liposomes. When the drug was stopped, the tumor volume grew to 2000mm 3 Or when the long diameter reached 20 mm (20th to 26th day after the initial administration), the mice were euthanized, and the heart, liver, spleen, lung and muscle tissues were obtained to prepare histopathological H&E sections. Microscopic imaging examinations did not reveal obvious pathological changes, indicating that under the experimental administration conditions, Mg-doxorubicin liposomes, folate receptor-targeted Mg-doxorubicin liposomes and ammonium sulfate doxorubicin liposomes did not cause obvious toxicity to normal tissues and organs.

[0081] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for preparing chemotherapeutic drug liposomes, characterized in that: The following steps are involved: S1) preparing liposomes with a weak salt gradient of magnesium ions; S2) mixing the liposomes having a magnesium ion weak salt gradient with an aqueous solution of anthraquinone drug molecules, heating, and purifying to obtain chemotherapeutic drug liposomes.

2. The preparation method according to claim 1, characterized in that: The step S1) is specifically as follows: A1) mixing lipid components in an organic solvent and removing the solvent to obtain a lipid film; the lipid components include phospholipid compounds and cholesterol; A2) hydrating the lipid film with an aqueous medium containing a weak salt of magnesium ions to obtain a liposome suspension; A3) subjecting the liposome suspension to nano-treatment to obtain nano-liposomes; A4) replacing the external aqueous phase of the nanoliposome with a solution containing no magnesium ion weak salt, to obtain liposomes with a magnesium ion weak salt gradient.

3. The preparation method according to claim 2, characterized in that: The phospholipid compounds include one or more of natural phospholipids, hydrogenated phospholipids, synthetic phospholipids, phospholipid-polyethylene glycol, phospholipid-polyethylene glycol-folic acid derivatives and other phospholipid-polyethylene glycol-tumor specific targeting molecule derivatives; The molar concentration of cholesterol in the lipid component is 20% to 45%; The organic solvent is selected from one or more of chloroform, ethanol and isopropanol.

4. The preparation method according to claim 2, characterized in that: The weak acid in the magnesium ion weak salt is selected from organic acids and / or organic hydrochlorides; the organic acid is selected from one or more of acetic acid, propionic acid, butyric acid, fumaric acid, maleic acid, gluconic acid, ascorbic acid, 4-hydroxyethylpiperazineethanesulfonic acid, 3-morpholinepropanesulfonic acid, aspartic acid and malonic acid; the organic hydrochloride is selected from one or more of tris(hydroxymethyl)aminomethane hydrochloride and / or triethylamine hydrochloride; The concentration of magnesium ions in the aqueous medium containing the magnesium ion weak acid salt is 0.15-1 mol / L.

5. The preparation method according to claim 2, characterized in that: The particle size of the nanoliposome is 50-200 nm.

6. The preparation method according to claim 2, characterized in that: In the step S4), the external aqueous phase of the nanoliposomes is replaced with a solution of a weak acid salt containing no magnesium ions by one or more treatments selected from column exchange, dialysis and ultrafiltration; the solution of a weak acid salt containing no magnesium ions is selected from sodium chloride solution, glucose solution or pH buffer solution.

7. The preparation method according to claim 1, characterized in that: The molar ratio of total lipids to anthraquinone drug molecules in the liposomes with a magnesium ion weak salt gradient in step S2) is 1:(0.1-0.5).

8. The preparation method according to claim 1, characterized in that: After mixing in step S2), an alkaline solution is added to adjust the pH value of the system to 7.4 to 8.5; And / or, the heating temperature in step S2) is 50° C. to 60° C.; the heating time is 5 to 15 minutes.

9. Chemotherapeutic drug liposomes prepared by the preparation method according to any one of claims 1 to 8.

10. Use of the chemotherapeutic drug liposome prepared by the preparation method according to any one of claims 1 to 8 in the preparation of drugs for treating tumors.